Cinven, a private investment firm, agreed to acquire a majority stake in BioAgilytix, a provider of molecular bioanalysis and bioanalytical test services, from Caledonia Investments, a London-based investment trust. Cobepa, a private investment firm, and GHO Capital will remain a significant minority investor in the company. Financial terms were not disclosed. "As we move into our next chapter of our evolution, Cinven will provide the additional resources that will empower us to expand not only our geographical reach but will also enable us to invest further in our talent and facilities around the globe to meet the ever-growing needs of our customers," Jim Datin, BioAgilytix President and CEO.